- Home
- AEMD vs THAR Comparison
AEMD vs THAR Comparison
Compare AEMD & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEMD
- THAR
- Stock Information
- Founded
- AEMD 1984
- THAR 2017
- Country
- AEMD United States
- THAR United States
- Employees
- AEMD N/A
- THAR N/A
- Industry
- AEMD Medical/Dental Instruments
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- AEMD Health Care
- THAR Health Care
- Exchange
- AEMD Nasdaq
- THAR Nasdaq
- Market Cap
- AEMD 4.1M
- THAR 3.3M
- IPO Year
- AEMD N/A
- THAR 2022
- Fundamental
- Price
- AEMD $1.22
- THAR $1.82
- Analyst Decision
- AEMD Strong Buy
- THAR Strong Buy
- Analyst Count
- AEMD 1
- THAR 1
- Target Price
- AEMD $56.00
- THAR $17.00
- AVG Volume (30 Days)
- AEMD 265.2K
- THAR 41.7K
- Earning Date
- AEMD 06-26-2025
- THAR 08-08-2025
- Dividend Yield
- AEMD N/A
- THAR N/A
- EPS Growth
- AEMD N/A
- THAR N/A
- EPS
- AEMD N/A
- THAR N/A
- Revenue
- AEMD N/A
- THAR N/A
- Revenue This Year
- AEMD N/A
- THAR N/A
- Revenue Next Year
- AEMD N/A
- THAR N/A
- P/E Ratio
- AEMD N/A
- THAR N/A
- Revenue Growth
- AEMD N/A
- THAR N/A
- 52 Week Low
- AEMD $1.20
- THAR $0.95
- 52 Week High
- AEMD $8.44
- THAR $6.39
- Technical
- Relative Strength Index (RSI)
- AEMD 41.34
- THAR 64.36
- Support Level
- AEMD $1.40
- THAR $1.30
- Resistance Level
- AEMD $2.88
- THAR $1.46
- Average True Range (ATR)
- AEMD 0.26
- THAR 0.14
- MACD
- AEMD -0.02
- THAR 0.02
- Stochastic Oscillator
- AEMD 36.49
- THAR 96.17
About AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.